Squarepoint’s Quest Diagnostics DGX Stock Holding History

Squarepoint’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,200	Closed	-$229K	–	4389
2025 Q3	$229K	Buy	+1,200	New	+$213K	﹤0.01%	3858
2025 Q2	–	Sell	-10,200	Closed	-$1.73M	–	4602
2025 Q1	$1.73M	Buy	10,200 +8,100	+386%	+$1.33M	﹤0.01%	2210
2024 Q4	$317K	Sell	2,100 -10,200	-83%	-$1.59M	﹤0.01%	4105
2024 Q3	$1.91M	Sell	12,300 -3,600	-23%	-$538K	﹤0.01%	2109
2024 Q2	$2.18M	Buy	+15,900	New	+$2.18M	﹤0.01%	1993
2023 Q4	–	Sell	-1,700	Closed	-$207K	–	4089
2023 Q3	$207K	Buy	+1,700	New	+$227K	﹤0.01%	3389

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Squarepoint's DGX Position: Q1 2026 in Review

Squarepoint reduced its Quest Diagnostics (DGX) stake by 39% in Q1 2026, selling an estimated $42.7M and leaving 345,788 shares worth $67.8M. The position accounts for 0.08% of the portfolio, ranked #247.

Squarepoint first reported a position in DGX in Q2 2015 and has held it in 37 quarters since. The position peaked at $151M in Q2 2025. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Squarepoint held 345,788 shares of Quest Diagnostics worth $67.8M as of Q1 2026.
Squarepoint sold 220,012 Quest Diagnostics shares in Q1 2026, an estimated $42.7M.
Quest Diagnostics made up 0.08% of Squarepoint's portfolio in Q1 2026, its #247 holding.
Squarepoint first reported a position in Quest Diagnostics in Q2 2015 and has held it in 37 quarters since.
Squarepoint's Quest Diagnostics position peaked at $151M in Q2 2025.
1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.